TIGIT and neoplasm: The genomic background of CRC, including alterations in KRAS, NRAS, PIK3CA, AKT1, BRAF, and the tumor’s MSI status, may modulate both the abundance and biological relevance of the immune regulators TIGIT and CD155, thereby affecting immune evasion and clinical outcome.